EYEN vs. PRQR, CNTX, SGMT, CYBN, RAPT, INCR, RZLT, IMAB, GOSS, and MCRB
Should you be buying Eyenovia stock or one of its competitors? The main competitors of Eyenovia include ProQR Therapeutics (PRQR), Context Therapeutics (CNTX), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), InterCure (INCR), Rezolute (RZLT), I-Mab (IMAB), Gossamer Bio (GOSS), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
ProQR Therapeutics (NASDAQ:PRQR) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking.
ProQR Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
Eyenovia has lower revenue, but higher earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
ProQR Therapeutics received 156 more outperform votes than Eyenovia when rated by MarketBeat users. However, 65.13% of users gave Eyenovia an outperform vote while only 61.86% of users gave ProQR Therapeutics an outperform vote.
In the previous week, Eyenovia had 3 more articles in the media than ProQR Therapeutics. MarketBeat recorded 6 mentions for Eyenovia and 3 mentions for ProQR Therapeutics. Eyenovia's average media sentiment score of 1.88 beat ProQR Therapeutics' score of 0.64 indicating that ProQR Therapeutics is being referred to more favorably in the media.
ProQR Therapeutics presently has a consensus target price of $3.38, suggesting a potential upside of 83.42%. Eyenovia has a consensus target price of $10.00, suggesting a potential upside of 1,340.51%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe Eyenovia is more favorable than ProQR Therapeutics.
Eyenovia has a net margin of 0.00% compared to Eyenovia's net margin of -260.75%. Eyenovia's return on equity of -61.58% beat ProQR Therapeutics' return on equity.
32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Eyenovia shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 7.1% of Eyenovia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ProQR Therapeutics beats Eyenovia on 9 of the 16 factors compared between the two stocks.
Get Eyenovia News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EYEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyenovia Competitors List
Related Companies and Tools
